High-grade osteosarcoma as a second primary neoplasm after breast cancer: diagnostic challenge of a thoracic mass
DOI:
https://doi.org/10.24054/4wgyg779Keywords:
Osteosarcoma, Breast Neoplasms, Chest Wall, Immunohistochemistry, Case ReportsAbstract
Introduction: High-grade surface osteosarcoma is a rare and aggressive bone malignancy. The occurrence of osteosarcoma as a second primary tumor in patients with a history of breast carcinoma is extremely uncommon and represents a diagnostic challenge, particularly when presenting as a thoracic mass initially suspected of metastasis. Case report: A 73-year-old woman with a history of breast carcinoma treated 15 years earlier presented with dyspnea and right pleural effusion. Computed tomography revealed a chest wall mass involving multiple ribs with pleural extension. Histopathology showed a malignant spindle-cell neoplasm with osteoid formation. Immunohistochemistry was positive for SATB2 and CD99 and negative for epithelial markers, confirming high-grade osteosarcoma. PET-CT demonstrated disseminated pulmonary and bone metastases. Multidisciplinary palliative management was established. Results: Morphological and immunohistochemical correlation allowed exclusion of metastatic breast carcinoma and confirmed high-grade osteosarcoma as a second primary malignancy diagnosed at an advanced stage. Conclusions: Osteosarcoma should be included in the differential diagnosis of new thoracic masses in patients with prior malignancy. Immunohistochemistry, particularly SATB2 expression, is essential for diagnosis. Multidisciplinary evaluation is crucial in advanced disease.
Downloads
References
Chan CM, Lindsay AD, Spiguel ARV, Gibbs CP Jr, Scarborough MT. Osteosarcoma perióstico: un estudio uniinstitucional de factores relacionados con los resultados oncológicos. Sarcoma. 2018;2018:8631237.
DOI: https://doi.org/10.1155/2018/8631237
Francis KC, Hutter RVP, Coley BL. Tratamiento del osteosarcoma. En: Pack GT, Ariel IM, editores. Treatment of Cancer and Allied Diseases. Vol. 2. New York: Harper & Row; 1964. p. 374-399.
Enlace (registro bibliográfico):
Dahlin DC, Coventry MB. Osteogenic sarcoma. A study of 600 cases. J Bone Joint Surg Am. 1967;49(1):101-110.
Enlace: https://pubmed.ncbi.nlm.nih.gov/5225072/
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
DOI: https://doi.org/10.3322/caac.21660
Travis LB, Rabkin CS, Boice JD Jr, Rowland JM, Friedman DL, Hammond S, et al. Second primary cancers after childhood cancer: an update of the childhood cancer survivor study. J Natl Cancer Inst. 2006;98(16):1158-1163.
DOI: https://doi.org/10.1093/jnci/djj331
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma etiology and epidemiology: current knowledge and future directions. Sarcoma. 2011;2011:17548.
DOI: https://doi.org/10.1155/2011/17548
Lewis WO, Huvos AG, Marcove RC. Primary osteosarcoma of the sternum: report of a case. J Bone Joint Surg Am. 1974;56(6):1343-1345.
Enlace: https://pubmed.ncbi.nlm.nih.gov/
Huang J, Yu CP, Chou YH, Yen CJ. Radiation-induced osteosarcoma of the sternum after radiotherapy for breast cancer. J Clin Oncol. 2007;25(15):2150-2151.
DOI: https://doi.org/10.1200/JCO.2006.09.5320
Doddapaneni D, Al-Obaidy K, Siddiqui H, Goudie C, Zhang X, Han H, et al. SATB2 is a sensitive and specific marker for osteosarcoma: a multi-institutional study. Mod Pathol. 2017;30(10):1395-1403.
DOI: https://doi.org/10.1038/modpathol.2017.71
Ferrari S, Palmerini E. Adjuvant and neoadjuvant chemotherapy for osteosarcoma. Curr Treat Options Oncol. 2018;19(1):1.
DOI: https://doi.org/10.1007/s11864-018-0515-2
Glare P, Plonk W, Temel J, Bakitas M. Palliative care for patients with advanced cancer. UpToDate. 2023.
Enlace: https://www.uptodate.com
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Cuidado y Ocupación Humana

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

